Griffis v. Blue Cross & Blue Shield of Alabama

590 So. 2d 270, 1991 Ala. LEXIS 691, 1991 WL 151550
CourtSupreme Court of Alabama
DecidedJuly 12, 1991
Docket1900839, 1900854
StatusPublished
Cited by4 cases

This text of 590 So. 2d 270 (Griffis v. Blue Cross & Blue Shield of Alabama) is published on Counsel Stack Legal Research, covering Supreme Court of Alabama primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Griffis v. Blue Cross & Blue Shield of Alabama, 590 So. 2d 270, 1991 Ala. LEXIS 691, 1991 WL 151550 (Ala. 1991).

Opinion

HOUSTON, Justice.

Jack Griffis sued Blue Cross and Blue Shield of Alabama (“Blue Cross”), seeking to recover damages for Blue Cross’s refusal to pay a claim under his medical insurance policy with Blue Cross. Griffis sought to recover under theories of breach of contract and the tort of bad faith refusal to pay an insurance claim. The trial court granted Blue Cross’s motion for a directed verdict on the bad faith claim, but denied Blue Cross’s motion for a directed verdict on the contract claim and submitted that claim to the jury, which returned a verdict for Griffis in the amount of $968.86. The trial court subsequently entered a judgment on that verdict. Griffis appealed that judgment to the Court of Civil Appeals, contending that the trial court had erred in granting Blue Cross’s motion for a directed verdict on his bad faith claim. Blue Cross cross-appealed, arguing that the trial court had erred in submitting the contract claim to the jury. The Court of Civil Appeals held that the trial court had properly submitted the contract claim to the jury, but, characterizing this as an “extraordinary” bad faith case, ruled that the trial court had erroneously directed a verdict for Blue Cross on the bad faith claim. Accordingly, the Court of Civil Appeals affirmed the judgment in part, reversed it in part, and remanded the case for a trial on Griffis’s bad faith claim. See Griffis v. Blue Cross & Blue Shield of Alabama, 590 So.2d 267 (Ala.Civ.App.1991). Both Griffis and Blue Cross sought certiorari review under Rule 39, A.R.APP.P.1 For the following reasons, we hold that the trial court properly directed a verdict for Blue Cross on the bad faith claim and, therefore, that the judgment of the Court of Civil Appeals pertaining to the bad faith claim is due to be reversed. Furthermore, because of our disposition of Blue Cross’s petition (1900839), we also hold that the issue raised by Griffis’s peti[272]*272tion (1900854) is moot and, consequently, that the writ in that case is due to be quashed as improvidently granted.

The evidence at trial showed the following: In 1986, Griffis underwent a magnetic resonance imaging scan (“MRI”)2 for the purpose of staging the progression of cancer of the prostate. The test was prescribed by Dr. Thomas Moody and performed and interpreted by Dr. Robert Naf-tel, a duly qualified diagnostic radiologist. Griffis submitted a claim to Blue Cross for the cost of the MRI. Blue Cross denied coverage, however, based on a provision in Griffis’s policy that excluded benefits for procedures considered by Blue Cross to be “experimental” or “investigative.” That provision, in pertinent part, provides:

“We will not provide benefits for the following, whether or not a physician performs or prescribes them:
[[Image here]]
“12. Any treatment, procedure, facilities, drugs, drug usage, equipment, or supplies which are experimental or investigative.”

The policy defines “experimental” or “investigative” as follows:

“12. ‘Experimental’ or ‘investigative’ means any treatment, procedure, facility, equipment, drugs, drug usage, or supplies either (a) not recognized by us as having scientifically established medical value and [as] being in accordance with generally accepted standards of medical practice or (b) not approved by a governmental agency from which approval is required.”

At the time the MRI was done on Griffis, Blue Cross did not recognize the use of MRIs for diagnosing cancer of the prostate “as having scientifically established medical value and [as] being in accordance with generally accepted standards of medical practice.” The use of MRIs for diagnosing conditions of the brain, spine, and limbs, however, was recognized by Blue Cross. Dr. Patrick Ryce,3 director of Blue Cross’s medical department, testified that it was his decision to place MRIs of the prostate on the company’s list of “experimental” or “investigative” procedures and that his decision was based on information that he had received in consultations with Blue Cross’s medical review committee, which consisted of practicing physicians who were not employed by Blue Cross,4 as well as on information that he had received from practicing radiologists who were experts in their field and had had hands-on experience with MRIs.5 Dr. Ryce also testified that he had reviewed various medical journals regarding new treatments and tests6 and that he had considered the recommendation [273]*273of the National Blue Cross and Blue Shield Association, a central organization that reviews new medical procedures and disseminates information to the approximately 78 Blue Cross and Blue Shield plans throughout the country. Dr. Ryce explained that Blue Cross’s list of “experimental” or “investigative” procedures was reevaluated continuously and that the list was revised approximately every six to eight weeks to reflect the technological advances that had been made in various procedures.

Dr. Naftel, testifying on behalf of Grif-fis, stated that he performed the MRI on Griffis for the purpose of discovering whether there had been any local progression of the cancer into the fat around the prostate gland or any metastasis into the pelvic region or into the lymph nodes. He testified that the staging of the disease would, in turn, affect the course of treatment. Dr. Naftel testified further that, in his opinion, the MRI used in evaluating Griffis’s condition was the safest and most effective method of obtaining the information sought and that it was superior to other existing means by which the information could be obtained. In addition, Dr. Naftel testified that he first began using MRIs in 1985 or 1986, principally to diagnose conditions of the brain and spine. He described his use of MRIs as being on the “cutting edge” of medicine in 1986 and he stated that the group with which he was associated was one of the first in the southeast to acquire an MRI machine and that that machine was “probably one of the first ten or fifteen in the country.” Dr. Naftel conceded that he had not conducted any studies or experiments to determine the effectiveness of MRIs in diagnosing prostate cancer. Dr. Naftel further conceded that in 1986 there was room for disagreement among medical professionals as to the effectiveness of MRIs. He testified as follows:

“Q. And in your case, I guess, with use of the MRI, it is, ... in your opinion, proven to be useful and effective; is that correct?
“A. That’s correct.
“Q. Now, back in 1985 or 1986 when it first came out, there was still some doubt about that; is that true?
“A. Well, I think in the general community, yes; in the general medical community.”

Dr. Moody, also testifying for Griffis, stated that the MRI, in conjunction with other diagnostic tests performed, enabled him to determine the proper treatment for Griffis and that he determined that Griffis would benefit from a radical prostatecto-my — the removal of the entire prostate gland. Dr. Moody testified further that the MRI had helped him determine that Griffis’s cancer was at a “potentially curable stage.”7

Arguing that it had a legitimate or debatable reason for concluding in 1986 that MRIs of the prostate were “experimental” or “investigative,” as those terms are de

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Emanuelsen v. State Farm Auto. Ins. Co.
651 So. 2d 29 (Court of Civil Appeals of Alabama, 1994)
Bishop v. State Auto. Mut. Ins. Co.
600 So. 2d 262 (Court of Civil Appeals of Alabama, 1992)
Griffis v. Blue Cross & Blue Shield of Alabama
590 So. 2d 278 (Court of Civil Appeals of Alabama, 1991)
Smith v. MBL Life Assur. Corp.
589 So. 2d 691 (Supreme Court of Alabama, 1991)

Cite This Page — Counsel Stack

Bluebook (online)
590 So. 2d 270, 1991 Ala. LEXIS 691, 1991 WL 151550, Counsel Stack Legal Research, https://law.counselstack.com/opinion/griffis-v-blue-cross-blue-shield-of-alabama-ala-1991.